RT Journal Article
SR Electronic
T1 Enzyme Kinetics of GTI-2040, a Phosphorothioate Oligonucleotide Targeting Ribonucleotide Reductase
JF Drug Metabolism and Disposition
JO Drug Metab Dispos
FD American Society for Pharmacology and Experimental Therapeutics
SP 2227
OP 2233
DO 10.1124/dmd.108.021295
VO 36
IS 11
A1 Wei, Xiaohui
A1 Dai, Guowei
A1 Liu, Zhongfa
A1 Cheng, Hao
A1 Xie, Zhiliang
A1 Klisovic, Rebecca
A1 Marcucci, Guido
A1 Chan, Kenneth K.
YR 2008
UL http://dmd.aspetjournals.org/content/36/11/2227.abstract
AB Enzyme kinetics of GTI-2040 (5′-GGC TAA ATC GCT CCA CCA AG-3′), a phosphorothioate ribonucleotide reductase antisense, were investigated for the first time in 3′ exonuclease solution and human liver microsomes (HLMs), using the ion-pair high-performance liquid chromatogram method for quantification of the parent drug and two major 3′N-1 and 3′N-2 metabolites. Enzyme kinetics of GTI-2040 in 3′-exonuclease solution were found to be well characterized by the Michaelis-Menten model, using the sum of formation rates of 3′N-1 and 3′N-2 (∼total metabolism) because of sequential metabolism. In HLMs, a biphasic binding was observed for GTI-2040 with high- and low-affinity constants (Kds) of 0.03 and 3.8 μM, respectively. Enzyme kinetics of GTI-2040 in HLMs were found to deviate from Michaelis-Menten kinetics when the total GTI-2040 substrate was used. However, after correction for the unbound fractions, the formation rate of total metabolites could be described by Michaelis-Menten kinetics. Using the free substrate fraction, the Km and Vmax of GTI-2040 were determined to be 6.33 ± 3.2 μM and 16.5 ± 8.4 nmol/mg/h, respectively. Using these values, in vitro hepatic intrinsic clearance (CLint) in HLM was estimated to be 2.61 ± 0.56 ml/h. The CLint was then used to predict GTI-2040's in vivo intrinsic clearance in humans by a microsomal protein scaling factor, which gave a mean value of 182.7 l/h, representing 24.1% of the observed in vivo mean scaled hepatic intrinsic clearance of 758.7 l/h in patients with acute myeloid leukemia. We concluded that the saturable nonspecific binding of GTI-2040 in HLMs complicated the interpretation of its enzyme kinetics, and scaled intrinsic clearance from HLMs only partially predicted the in vivo intrinsic clearance. The American Society for Pharmacology and Experimental Therapeutics